Skip to main content
OpenTrials
Completed

NCT Number: NCT02753270

Catheter-directed Foam Sclerotherapy With Tumescence

Foam sclerotherapy has been established as another option of treatment for varicose veins of the lower limbs. Its advantages are the application to patients with high surgical risk and immediate return to usual activities. Comparing to laser and radiofrequency, it has lower cost and is less painful. Nevertheless, it requires more re-interventions due to venous recanalization.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The aim of this study is to compare two ultrasound guided foam sclerotherapy (UGFS) techniques to great saphenous vein (GSV) by injecting the sclerosant foam through a short catheter without perivenous tumescence and through a long catheter with saline anesthetic tumescence. Method: selection of 50 patients with primary varicose veins, edema (C3EpAsPr of the CEAP classification) and with GSV measuring 6 - 10 mm, 3 cm below the saphenofemoral junction, identified by ultrasound. The study is taking place at the vascular surgery ambulatory of the University of São Paulo. It is a prospective controlled trial with random allocation in two groups according to the foam sclerosant technique injection. The group 1 will receive the sclerosant foam by a short catheter 18 G and in the group 2 an angiographic catheter 4 Fr. will be used. All patients will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method. The access will be by puncture and its place will depend on the insufficient venous extension. It will be at the level of the knee to treat proximal GSV or at the medial ankle to treat the full length of the vein. In group 2, after inserting the long catheter into the GSV, a saline anesthetic solution will be infiltrated around the insufficient venous segment under ultrasound guidance to reduce its diameter. The long catheter will be continuously flushed with 0.9% saline solution until the foam sclerosant injection. In the cases of treating only the proximal GSV, patients will receive a continuous compression with tourniquet below the knee just before the injection and maintained for 5 minutes thereafter. Then, the tributaries in all 50 patients will be treated by phlebectomy under tumescent local anesthesia. Color-duplex ultrasound follow-up is programmed to 7, 28 and 168 days after the treatment. The first one is to check the possibility of deep venous thrombosis, the second is to verify the occlusion rate and the need of another foam injection. The last ultrasound is to check the final occlusion rate.

Hypothesis: UGFS with long catheter preceded of tumescence has a large occlusion rate of the GSV with monotherapy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age equal to or greater than 18 years;
  • patients with varicose veins with edema - CEAP classification C3EpAsPr;
  • Great saphenous vein incompetence, segmental and total, with diameter from 6 to 10 mm in proximal thigh, 3 cm from the saphenous femoral junction measured by ultrasound.

Exclusion criteria

  • Allergy to the sclerosant substance;
  • acute deep vein thrombosis or pulmonary thromboembolism;
  • local infection in the area of sclerotherapy or severe systemic infection;
  • prolonged immobilisation;
  • symptomatic patent foramen ovale;
  • pregnancy;
  • peripheral arterial occlusive disease;
  • short saphenous vein incompetence association;
  • refusal to sign the consent form;
  • nonadherence to outpatient treatment.

Treatment and study plan

Short catheter

Procedure

Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.

Long catheter preceded by tumescence

Procedure

Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.

Primary outcomes

  1. Great Saphenous Vein Occlusion Rate

    Time frame: Six months after the intervention

    It will be measured by ultrasound

Secondary outcomes

  1. Quality of Life Change

    Time frame: Six months follow-up after the intervention

    It will be measured by the application of the Aberdeen varicose vein questionnaire

  2. Complications

    Time frame: From the intervention until six months follow-up

    It will be considered:

    • anaphylaxis;
    • superficial thrombophlebitis;
    • deep venous thrombosis;
    • pulmonary embolism;
    • visual disturbances;
    • migraine;
    • transient ischemic attack;
    • tissue necrosis;
    • intra arterial injection;
    • neurological injury;
    • edema;
    • skin pigmentation;
    • skin irritation;
    • burning after the sclerosant injection;
    • retaining clots.

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Registry information

Official study title

Catheter-directed Foam Sclerotherapy With Tumescence of the Great Saphenous Vein Versus Ultrasound Guided Foam Sclerotherapy: Randomised Controlled Trial

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Apr 27, 2016
Registry last updated
Nov 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.